Skip to content
DataLookout
Menu

KeTADiDNCT07943741

Ketamine for Treatment of Alzheimers Disease Related Depression

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Feasibility of the Study as Measured by the Number of Participants Completing the Study
Timeframe: From enrollment to the end of safety monitoring at 8 weeks
Safety, as Measured by the Number of Participants with At Least One Treatment-Emergent Adverse Event
Timeframe: From the first medication infusion through study completion at 8 weeks
Clinician-Administered Dissociative States Scale (CADSS) Total Score
Timeframe: Week 1 Infusion 1, Week 1 Infusion 2, Week 2 Infusion 1, and Week 2 Infusion 2 prior to and 40 and 90 minutes after the start of each infusion.
Severity of Suicidal Thoughts with Montgomery-Åsberg Depression Rating Scale (MADRS) Item 10 Score
Timeframe: From enrollment to the end of safety monitoring at 8 weeks
Change in Severity of Suicidal Ideation as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: Screening (baseline), Week 1 Infusion 2, Week 2 Infusion 2
Change in Suicidal Behavior as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: Screening (baseline), Week 1 Infusion 2, Week 2 Infusion 2
Number of Treatment-Emergent Side Effects as Measured by the Treatment-Emergent Symptom Scale (TESS)
Timeframe: Week 1 (Infusions 1 and 2), Week 2 (Infusions 1 and 2), Week 3, Week 4, and Week 8
Severity of Treatment-Emergent Side Effects as Measured by the Treatment-Emergent Symptom Scale (TESS)
Timeframe: Week 1 (Infusions 1 and 2), Week 2 (Infusions 1 and 2), Week 3, Week 4, and Week 8
Acceptability of the intervention as measured by the Acceptability of Intervention Measure (AIM)
Timeframe: Week 4 (approximately 2 weeks after the final medication infusion)

Secondary (1)

Change in MADRS (Montgomery Asberg Depression Rating Scale) Score

Arms and interventions

KetamineExperimental
Active Placebo (Midazolam)Placebo comparator

Drugs: Ketamine and saline, Active Placebo (Midazolam) Infusion

Sites

1 site in 1 country

  • Vanderbilt Psychiatric HospitalNashville, Tennessee, United States